… mechanism-based modeling approaches for pharmacodynamic interactions have been
described … , is pharmacokinetic drug interactions. Of particular concern are interactions leading to …

… interaction mechanisms should be appropriately defined by linking the models of the substrate
and the interacting drug. If a metabolite is involved in a drug–drug interaction, a model for …

… , physiologically based pharmacokinetic models, and machine learning models. PD DDI
methods involve in vivo comparative efficacy studies and in vitro static and dynamic tests (as …

… physiologically based pharmacokinetic (PBPK) parent−metabolite model of carbamazepine
… , to be applied for drug–drug interaction (DDI) prediction. The model was developed in PK-…

… We predicted the drug–drug interaction (DDI) potential of siponimod in presence of … by
physiologically-based pharmacokinetic (PK) modeling. The model was established using in vitro …

… physiologically based pharmacokinetic model integrating … drug–drug interactions (DDIs)
involving inhibitory and inducing effects on multiple CYPs as often encountered with HIV drugs. …

… pharmacokinetic (PK) based drug–drug interactions (DDI) is essential for ensuring patient
safety and drug … the market and drug development, evaluation of TP-drug interaction (TPDI) …

… We studied if the clinical pharmacokinetics and drug–drug interactions (DDIs) of the … -based
pharmacokinetic modeling approach. To this end, a glibenclamide PBPK-model was build in …

… Rosuvastatin is a frequently used probe in transporter-mediated drug-drug interaction (DDI) …
based pharmacokinetic (PBPK) model of rosuvastatin for prediction of pharmacokinetic (PK) …

… expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational
new drug and other drugs should be conducted during drug development as part of an …